Ray, E.C., Boyd-Shiwarski, C.R., Liu, P.F., Novacic, D. and Cassiman, D. (2020) SGLT2 Inhibitors for Treatment of Refractory Hypomagnesemia: A Case Report of 3 Patients. Kidney Medicine, 2, 359-364.
https://doi.org/10.1016/j.xkme.2020.01.010

has been cited by the following article:

• TITLE: Metabolic and Renal Protective Benefits of Magnesium Supplementation in the Long-Term Management of Patients with Type 2 Diabetes Mellitus

  AUTHORS: Richard Evers Katholi, Marcella Rene Ervin

  KEYWORDS: Hypomagnesemia, Contrast-Induced Nephropathy, Renal Function, SGLT2 Inhibitors, Type 2 Diabetes Mellitus

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.13 No.2, May 10, 2023

  ABSTRACT: Magnesium deficiency is common in patients with type 2 diabetes mellitus (type 2 DM). When adequate magnesium supplementation is chronically given, patients with type 2 DM appear to have improved glucose control and may have delayed chronic complications. In addition, magnesium supplementation may slow the progression of chronic kidney disease (CKD) and decrease the risk of contrast-induced nephropathy in patients with type 2 DM. Keeping serum magnesium at 2.0 mEq/L or greater appears to accomplish these benefits for patients with type 2 DM. Periodically measuring serum magnesium and estimated glomerular filtration rate (eGFR) allows a physician to adjust the supplemental magnesium dose to accomplish these therapeutic goals while avoiding hypermagnesemia.